Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Channa striata Extract and Curcumin in Advanced Lung Cancer
NCT07906626Completed
- Sponsor
- Universitas Sumatera Utara
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Randomised, double-blind trial of VipaAlim and curcumin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Universitas Sumatera Utara. Primary endpoint: Change from baseline in body weight at 9 weeks. Started Jul 2025; status: completed.
02
Drugs
VipaAlimcurcumin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07906626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906626.